Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 839 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Aiming to Support Cancer Research, ESMO Calls on the European Council... August 28, 2026 Hospice Nurse Fired from Job After Being Diagnosed with Breast Cancer September 30, 2019 The Power of Fruits and Vegetables December 18, 2020 Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow April 12, 2023 Load more HOT NEWS Keeping A Jasmine Plant In Your Room Reduces Anxiety, Panic Attacks... Population Mortality from NSCLC in the US Fell Sharply Due to... Medicare Open Enrollment is Almost Here-What You Need to Know for... Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy...
